Table 3 Summary the treatment of tocilizumab for TRAPS
case | 1 | 2 | 3 | 4 |
|---|---|---|---|---|
Ancestry | ND | ND | ND | ND |
Age | 52Y | 49Y | 30Y | 6Y |
Gender | M | M | F | M |
Onset of symptoms | 5Y | ND | 7Y | 4Y |
Gene mutation | C33Y | R92Q | no identified variant | C96R |
Clinical phenotype | recurrent fevers, myalgia, rash, abdominal pains, joint pains, and lymphadenopathy | fever, recurrent annular erythematous plaques, conjunctivitis | high fever, nausea, rashes, migratory myalgia, joint pain | fever, arthritis, skin rash, vomiting, diarrhea, unilateral periorbital edema |
Treatment prior to TCZ | corticosteroids, etanercept, anakinra | methotrexate, salazopyrin, hydroxychloroquine, infliximab, etanercept | prednisolone, etanercept, colchicine, | indomethacin, ibuprofen, hydroxychlorochine, cyclosporine A, methotrexate, infliximab |
TCZ dose (mg/kg) and route of administration | 8 IV | 8 IV | 8 IV | 8 IV |
Frequency of administration (weeks) | 4 | 4 | every 2 weeks then PRN | 4 |
Duration of treatment (months) | 6months | 6months | 26months | 42months |
Adverse events | Trombocytopenia | ND | ND | ND |
Outcome Clinical | CR | CR | CR | CR |
Reference | Vaitla et al. (2011) [23] | Akasbi et al.(2015) [24] | Hosoya et al. (2015) [25] | Torre et al. (2015) [26] |